BIOCONTROL TECHNOLOGY INC
8-K, 2000-02-02
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: XTRA CORP /DE/, 8-K, 2000-02-02
Next: ROBOTIC VISION SYSTEMS INC, S-3/A, 2000-02-02





               SECURITIES AND EXCHANGE COMMISSION

                     Washington, D.C.  20549

                            FORM 8-K

                         CURRENT REPORT

             Pursuant to Section 13 or 15(d) of the
                 Securities Exchange Act of 1934

                       ___________________


Date of Report (Date of earliest event reported) January 25, 2000

                    BIOCONTROL TECHNOLOGY, INC.
     (Exact name of registrant as specified in its charter)


  Pennsylvania                       0-10822                   25-1229323
 (State of other jurisdiction   (Commission File Number)    (IRS Employer
   of incorporation)                                       Identification No.)


      300 Indian Springs Road, Indiana, Pennsylvania 15701
    (Address of principal executive offices)           (Zip Code)


Registrant's telephone number, including area code (412) 349-1811



_________________________________________________________________
                 (Former name or former address,
                  if changes since last report.)







Item 1.   Change in Control of Registrant.
          Not applicable.

Item 2.   Acquisition or Disposition of Assets.
          Not applicable.

Item 3.   Bankruptcy or Receivership.
          Not applicable.

Item 4.   Changes in Registrant's Certifying Accountant
          Not applicable.

Item 5.   Other Events.

          Biocontrol Technology, Inc. subsidiary, Diasensor.com,
          Inc., in conjunction with MicroIslet, Inc, of San
          Diego, CA, is pleased to announce an alliance that has
          been initiated with a strategic investment by
          Diasensor.com into MicroIslet.  With an initial equity
          investment of $500,000, Diasensor.com will receive a
          10% stake with an option to purchase an additional 10%
          in the future.  Diasensor.com's investment in
          MicroIslet demonstrates a commitment of the company and
          its parent, Biocontrol Technology, to work towards a
          cure for diabetes and improved quality of life for
          those who suffer from the disease.

Item 6.   Resignation of Registrant's Directors.
          Not Applicable

Item 7.   Financial Statement, Pro Forma Financial Information and Exhibits.

          (a)  Financial Statements and Businesses Acquired - Not Applicable.
          (b)  Pro Forma Financial Information - Not Applicable.
          (c)  Exhibits - Press Release.

                           SIGNATURES

      Pursuant to the requirement of the Securities Exchange  Act
of  1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.

                                   BIOCONTROL TECHNOLOGY, INC.

                                   by  /s/   Fred E. Cooper
                                             Fred E. Cooper, CEO
DATED:  January 25, 2000




                                                 BICO
                                       BIOCONTROL TECHNOLOGY, INC
                            2275 Swallow Hill Road, Building 2500
                                            Pittsburgh, PA  15220
Press Release

Investors                                              Media
Diane McQuaide                                         Susan Taylor
1.412.429.0673  phone                                  1.412.429.0673 phone
1.412.279.9690  fax                                    1.412.279.5041 fax

   BIOCONTROL TECHNOLOGY, INC.'S SUBSIDIARY, DIASENSOR.COM, INVESTS
         IN MICROISLET, INC. TO FIND A CURE FOR DIABETES


     Pittsburgh,  PA - January 25, 2000 - Biocontrol  Technology,
Inc.   (OTCBB:BICO)    subsidiary,   Diasensor.com,   Inc.,    in
conjunction with MicroIslet, Inc. of San Diego, CA, is pleased to
announce  an  alliance that has been initiated with  a  strategic
investment  by  Diasensor.com into MicroIslet.  With  an  initial
equity investment of $500,000, Diasensor.com will receive  a  10%
stake with an option to purchase an additional 10% in the future.

     MicroIslet  has  licensed  several  technologies  from  Duke
University that have been developed over the last decade  by  Dr.
Emmanuel  Opara, Ph.D., Director of Islet Transplant Research  at
the  Duke  Medical  Center.   The Duke/MicroIslet  technology  is
unique  in  that it is a comprehensive multi-disciplinary  system
developed  with  the  goal of curing insulin dependent  diabetes.
Optimization  of  the microencapsulated islet for transplantation
is  the  focus of the Duke/MicroIslet effort.  Dr. Opara and  his
staff  have  demonstrated  a  proprietary  methodology  for   the
isolation, culture, storage, and immunoprotection of islet cells.

     Diasensor.com's  investment  in  MicroIslet  demonstrates  a
commitment  of the company and its parent, Biocontrol Technology,
to  work towards a cure for diabetes and improved quality of life
for  those who suffer from the disease.  Diasensor.com  owns  the
patent,  marketing and distribution rights to the  Diasensorr2000
noninvasive  glucose  monitor  currently  in  the  FDA   approval
process.   Biocontrol Technology developed and  manufactures  the
monitor.

     More than 16 million people in the U.S. are currently living
     with  diabetes, and approximately 4 million of these  people
     require  daily  insulin therapy to help  them  manage  their
     disease.   People  with Type I diabetes do not  produce  any
     insulin  because the insulin producing beta cells have  been
     destroyed  by  autoimmune  reaction.   People  with  Type  I
     diabetes require self-monitoring of blood glucose, a  strict
     diet,  and  constant  administration of  insulin.   Although
     people  with  Type  II  diabetes  produce  some  insulin,  a
     significant  percentage  of  these  patients  also   require
     insulin  injections.  These populations  would  benefit  the
     greatest   from  transplanted  islets  to  restore  normally
     functioning,  insulin  producing  cells  instead   of   only
     treating symptoms of the disease.  It is estimated  that  in
     excess of 100 billion dollars is spent annually in the  U.S.
     on both the direct and indirect costs related to diabetes.

      John F. Steel IV, President & CEO of MicroIslet stated that
current  funding activity is to be used for expanded pre-clinical
research  in  non-human primates at the Duke  University  Medical
Center  and other corporate purposes.  Mr. Steel, who has Type  I
diabetes,  further  commented that reducing or  eliminating  that
need for frequent insulin injections and blood-glucose monitoring
would  be  a  major  milestone in the  day-to-day  management  of
diabetes.   "A curative therapy has the potential to dramatically
reduce  the  burden  the  diabetes epidemic  is  placing  on  the
national health care system."

      Fred  E. Cooper, CEO of Biocontrol Technology, Inc.,  added
that   the   early   stage   investment  in   MicroIslet   allows
Diasensor.com  to  expand  on  its  diabetes  interests  with   a
technology  that  may  potentially provide  a  cure  for  insulin
dependent diabetes.

     Biocontrol   Technology  has  its   corporate   offices   in
     Pittsburgh,  PA  and  is  involved in  the  development  and
     manufacture   of   biomedical  devices   and   environmental
     products.  Biocontrol  owns 52% of Diasensor.com,  which  is
     also located in Pittsburgh, PA.






WEBSITE:  www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER:  1.800.357.6204





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission